MFDS Conducts Intensive Inspection of Vitamin and Other Labeling and Advertising Ahead of Family Month View original image


[Asia Economy Reporter Cho Hyun-ui] The Ministry of Food and Drug Safety will conduct an intensive inspection of labeling and advertising for pharmaceuticals, biopharmaceuticals, and quasi-drugs expected to see increased demand during the Family Month in May, from the 23rd to the 29th.


According to the Ministry on the 22nd, this inspection is a biannual intensive check conducted according to the basic plan for manufacturing and distribution management of pharmaceuticals established annually, with participation from all 17 cities and provinces nationwide.


The main inspection targets are ▲ pharmaceuticals with high demand such as vitamins ▲ biopharmaceuticals with high recognition and large distribution volume such as botulinum toxin preparations ▲ quasi-drugs with seasonal demand such as repellents. The inspection covers ▲ appropriateness of labeling on containers and packaging of over-the-counter drugs ▲ advertisements and printed materials, TV, radio, newspaper, and online media advertisements ▲ provision of information beyond the scope of approved matters.


The Ministry of Food and Drug Safety mandatorily inspects companies subject to administrative guidance from last year and assigns target items by city and province to improve work efficiency. The inspection results will be discussed at future meetings of the labeling and advertising consultative body operated between the Ministry and local governments.



Lee Eui-kyung, Commissioner of the Ministry of Food and Drug Safety, stated, “Through this inspection, we aim to create an environment where the public can use medical products with confidence, and we plan to take strict measures such as administrative sanctions including suspension of business and criminal prosecution against intentional illegal activities.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing